SCHEMBL4777284

SCHEMBL4777284

CC(C)NC(=O)c1ccc(NS(=O)(=O)CCc2ccccc2Cl)cc1

nearest known ligand 0.49

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ACLY P53396 1/20 0.49
PTGES2 Q9H7Z7 1/20 0.46
HIF1A Q16665 1/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
L3MBTL1 Q9Y468 2/20 0.42
HPGD P15428 2/20 0.41
LMNA P02545 1/20 0.41
TRPV1 Q8NER1 1/20 0.41
TSHR P16473 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
HTT P42858 1/20 0.40
MAPT P10636 1/20 0.40
RAB9A P51151 1/20 0.40
POLB P06746 1/20 0.40
NAMPT P43490 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4768066 0.87 PTGES2 (0.49) PTGES2HIF1ASMN1; SMN2L3MBTL1HPGD
SCHEMBL4776613 0.85 HIF1A (0.50) PTGES2HIF1ASMN1; SMN2L3MBTL1HPGD
SCHEMBL4774741 0.84 HPGD (0.58) PTGES2SMN1; SMN2L3MBTL1HPGDLMNA
SCHEMBL4777693 0.83 HIF1A (0.54) PTGES2HIF1ASMN1; SMN2L3MBTL1HPGD
SCHEMBL4773056 0.82 ALDH1A1 (0.46) SMN1; SMN2LMNAMEN1KMT2A
SCHEMBL4778522 0.82 ALDH1A1 (0.46) SMN1; SMN2LMNAMEN1KMT2A
SCHEMBL4772410 0.81 HIF1A (0.55) PTGES2HIF1ASMN1; SMN2L3MBTL1HPGD
SCHEMBL4770958 0.81 HIF1A (0.52) PTGES2HIF1ASMN1; SMN2L3MBTL1HPGD
SCHEMBL4771196 0.79 SMN1; SMN2 (0.53) PTGES2HIF1ASMN1; SMN2L3MBTL1TRPV1
SCHEMBL4778580 0.75 SMN1; SMN2 (0.44) HIF1ASMN1; SMN2L3MBTL1HPGDLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 ACLY 1795/4885PTGES2 4324/4885HIF1A 4386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.